Nestlé and Cedars-Sinai Medical Center participated in a round that came four months after the precision IBD therapy developer rebranded from Precision IBD.
Prometheus Biosciences, a US-based developer of treatments for inflammatory bowel disease (IBD), closed $130m in financing yesterday from investors including healthcare provider Cedars-Sinai Medical Center and food product manufacturer Nestlé.
Eventide Asset Management and RTW Investments co-led the round, which also featured Perceptive Advisors, Cormorant Capital, Cowen Healthcare Investments, Ascend Global Investment Fund, Point72 Asset Management and Irving Investors.
Founded in 2016 as Precision IBD, Prometheus is developing precision medicine and diagnostics technology for gastroenterology and autoimmune diseases, and is…
